知情人士向Moneycontrol透露，由德国SCHOTT Pharma和私募股权公司TPG Growth支持的SCHOTT Poonawalla，已启动国内首次公开募股（IPO）的初步步骤。这家总部位于孟买的公司是印度制药和生物技术行业的主要初级包装提供商。如果上市计划落实，它将加入越来越多利用国内IPO市场的跨国公司及其印度子公司的行列。该公司的少数投资者包括由亿万富翁阿达尔·普纳瓦拉领导的疫苗制造商印度血清研究所。
SCHOTT Poonawalla, backed by Germany's SCHOTT Pharma and private equity firm TPG Growth, has initiated preliminary steps for a domestic initial public offering , people familiar with the matter told Moneycontrol. The Mumbai-based company is a leading primary packaging provider for India's pharmaceutical and biotechnology industries. If the listing plans materialise, it would join a growing list of multinational companies and their Indian subsidiaries tapping the domestic IPO market.
上述知情人士之一表示：“SCHOTT Poonawalla已邀请投行下周为拟议的IPO进行推介。目前还处于早期阶段，但截至目前，意图是筹集约4亿美元。”该人士谨慎表示，发行规模和估值尚未最终确定，可能会根据市场情况发生变化。
第二位知情人士也证实了这一进展，并表示拟议的发行可能包括新股发行和现有股东出售股份的组合。
The company counts Serum Institute of India, the vaccine maker led by billionaire Adar Poonawalla, as a minority investor.“SCHOTT Poonawalla has invited investment banks to make pitches for the proposed IPO next week. These are early days, but as of now, the intent is to raise around $400 million,” one of the persons cited above said, cautioning that the issue size and valuation have not been finalised and could change depending on market conditions.A second person confirmed the development and said the proposed issue would likely comprise a combination of fresh shares and an offer for sale.“The IPO provides a window for investor Serum Institute of India to further dilute part stake if deemed fit,” a third person said.A fourth person also confirmed the listing plans.
第三位知情人士表示：“IPO为投资者印度血清研究所提供了进一步稀释部分股权的窗口，如果认为合适的话。”第四位知情人士也证实了上市计划。
上述四人均要求匿名，向Moneycontrol提供了上述信息。
All four people spoke to Moneycontrol on condition of anonymity.
截至发稿时，SCHOTT Poonawalla尚未回复电子邮件置评请求。TPG和印度血清研究所均拒绝置评。
SCHOTT Pharma的一位发言人表示：“作为原则，我们不对市场猜测或潜在的未来交易发表评论。”
An email query to SCHOTT Poonawalla remained unanswered at the time of publication. TPG and Serum Institute of India declined to comment.A spokesperson for SCHOTT Pharma said, “As a matter of principle, we do not comment on market speculation or potential future transactions.”
总部位于德国的SCHOTT Pharma专注于药物容器和输送解决方案，持有SCHOTT Poonawalla 50%的股份，而TPG Growth持有35%。该公司最初是SCHOTT Pharma与印度血清研究所的50:50合资企业。
Germany-based SCHOTT Pharma, which specialises in drug containment and delivery solutions, holds a 50% stake in SCHOTT Poonawalla, while TPG Growth holds 35%. The company was originally a 50:50 joint venture between SCHOTT Pharma and Serum Institute of India.
2025年5月6日，SCHOTT Pharma宣布与TPG达成具有约束力的协议，将合资企业35%的股份出售给该私募股权公司。
On May 6, 2025, SCHOTT Pharma announced a binding agreement with TPG to sell a 35% stake in the joint venture to the private equity firm.
Novo Holdings 与 TPG Growth 共同投资。Moneycontrol 于 2024 年 11 月 28 日首次报道，TPG Growth 与印度血清研究所正就出售股份进行谈判。报道称：“SCHOTT Poonawalla 是一项独特的资产，也是一家明确的市场领导者，在注射剂包装领域拥有超过 50% 的市场份额，因此 TPG 看到了机会。”报道补充称，该公司的股权估值约为 8 亿美元。
Novo Holdings joined TPG Growth as a co-investor. Moneycontrol was the first to report, on November 28, 2024, that TPG Growth and Serum Institute of India were in talks over a stake sale.“SCHOTT Poonawalla is a unique asset and a clear market leader with an over 50 percent market share in injectable packaging and hence TPG saw an opportunity,” the report said, adding that the company's equity valuation was estimated at around $800 million.
在 TPG 支持的医疗保健公司中，Manipal Health Enterprises、Sai Life Sciences 和 Dr Agarwal's Health Care 已在印度上市。在印度包装行业，SCHOTT Poonawalla 的上市同行包括 EPL Ltd、AGI Greenpac、Uflex Ltd、TCPL Packaging 和 Jindal Poly Films。现代汽车印度、LG Electronics India、Orkla India 和 Tenneco Clean Air India 是近年来在印度发起 IPO 的跨国公司之一。
Manipal Health Enterprises, Sai Life Sciences and Dr Agarwal's Health Care are among the healthcare companies backed by TPG that have made their stock market debuts in India. In India's packaging sector, SCHOTT Poonawalla's listed peers include EPL Ltd, AGI Greenpac, Uflex Ltd, TCPL Packaging and Jindal Poly Films. Hyundai Motor India, LG Electronics India, Orkla India and Tenneco Clean Air India are among the multinational companies that have launched IPOs in India in recent years.
Pernod Ricard 和 Carlsberg 的印度分公司也在筹备中。本周早些时候，动力传输和驱动解决方案公司 Bonfiglioli Transmissions 253.4 亿卢比的 IPO（完全由其意大利发起人发售）获得了 46 倍的认购。聚焦 SCHOTT PoonawallaSCHOTT Poonawalla 的产品组合包括用于自动注射笔的药筒、用于多种生物制剂的预充式注射器、西林瓶和安瓿瓶。
The Indian arms of Pernod Ricard and Carlsberg are also in the pipeline. Earlier this week, the Rs 2,534-crore IPO of power transmission and drive solutions company Bonfiglioli Transmissions, entirely an offer for sale by its Italian promoter, was subscribed 46 times. Lens on SCHOTT PoonawallaSCHOTT Poonawalla's product portfolio includes cartridges for auto-injector pens, prefillable syringes for a range of biologic drugs, vials and ampoules.
它还为生物技术和制药公司以及合同开发和制造组织提供监管服务。通过与 SCHOTT Pharma 的合作，该公司利用了数十年在药品包装方面的专业知识，涵盖药物给药、临床试验、监管流程和商业申报。谈及 TPG 于 2025 年 5 月进入 SCHOTT Poonawalla，SCHOTT Pharma 首席执行官 Andreas Reisse 曾表示：“印度继续是 SCHOTT Pharma 最具活力和战略重要性的制造中心之一。”
It also offers regulatory services to biotechnology and pharmaceutical companies and contract development and manufacturing organisations .Through its association with SCHOTT Pharma, the company draws on decades of expertise in pharmaceutical packaging, spanning drug administration, clinical trials, regulatory processes and commercial filings.
欢迎 TPG 加入合作伙伴关系，标志着我们合作向前迈出了令人振奋的一步。SCHOTT Pharma（肖特制药）的创新能力和对注射剂的纯专注将得到 TPG 在印度医疗保健领域强大影响力所带来的本地市场专业知识、人脉关系和经验的补充。随着我们持续扩大本地产能并巩固在印度市场的领先地位，我们有信心这一举措将进一步提升我们的全球版图，并为客户创造卓越价值。
Speaking about TPG's entry into SCHOTT Poonawalla in May 2025, SCHOTT Pharma CEO Andreas Reisse had said: “India continues to be one of the most dynamic and strategically important manufacturing hubs for SCHOTT Pharma. Welcoming TPG to the partnership marks an exciting step forward in our collaboration. SCHOTT Pharma’s innovation capabilities and pure-play focus on injectables will be complemented by TPG’s local market expertise, relationships, and experience from its strong presence in the Indian healthcare sector. As we continue to expand our local production capacities and leading role in the Indian market, we are confident that this step will further enhance our global footprint and deliver exceptional value to our customers.”